Halozyme Therapeutics
HALO Nasdaq
SEC CIK 1159036 LEI 529900242I3SV9AGM753
Follow Halozyme Therapeutics
Weekly email: filings, results
Revenue, last quarter
$493M
+39.2% vs same quarter last year
Net income
$247M
+41% vs same quarter last year
EPS, diluted
$2.01
+40.6% vs same quarter last year
Operating cash flow
$258.3M
+44.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.4B | $316.9M |
| FY24 | $1B | $444.1M |
| FY23 | $829.3M | $281.6M |
| FY22 | $660.1M | $202.1M |
| FY21 | $443.3M | $402.7M |
| FY20 | $267.6M | $129.1M |
| FY19 | $196M | −$72.2M |
| FY18 | $151.9M | −$80.3M |
| FY17 | $316.6M | $63M |
| FY16 | $146.7M | −$103M |
| FY15 | $135.1M | −$32.2M |
| FY14 | $75.3M | −$68.4M |
| FY13 | $54.8M | −$83.5M |
| FY12 | $42.3M | −$53.6M |
| FY11 | $56.1M | −$19.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 83.6% | 33.6% | 22.7% |
| FY24 | 84.3% | 54.3% | 43.7% |
| FY23 | 76.8% | 40.7% | 34% |
| FY22 | 78.9% | 40.5% | 30.6% |
| FY21 | 81.6% | 62.2% | 90.8% |
| FY20 | 83.8% | 53.9% | 48.2% |
| FY19 | 76.8% | −34.5% | −36.9% |
| FY18 | 93.3% | −45.7% | −52.9% |
| FY17 | 90.2% | 25.6% | 19.9% |
| FY16 | 77.4% | −56.7% | −70.2% |
| FY15 | 78.3% | −20.3% | −23.9% |
| FY14 | 69.8% | −83.7% | −90.8% |
| FY13 | 88.6% | −146.8% | −152.3% |
| FY12 | 97.4% | −126.7% | −126.5% |
| FY11 | 99.5% | −35.4% | −35.2% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $644.6M |
| FY24 | $468.4M |
| FY23 | $373.3M |
| FY22 | $235.3M |
| FY21 | $298M |
| FY20 | $53M |
| FY19 | −$89.5M |
| FY18 | −$54.2M |
| FY17 | $132.7M |
| FY16 | −$53.5M |
| FY15 | −$39.4M |
| FY14 | −$48.9M |
| FY13 | −$51.6M |
| FY12 | −$65.7M |
| FY11 | −$35.1M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $342.4M |
| FY24 | $250M |
| FY23 | $402.4M |
| FY22 | $200M |
| FY21 | $350.1M |
| FY20 | $150.1M |
| FY19 | $200M |
| FY18 | $0 |
| FY17 | $0 |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Halozyme Therapeutics
- Healthcare median
Show the numbers
| Year | Halozyme Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 22.7% | −30.6% |
| FY24 | 43.7% | −47% |
| FY23 | 34% | −58% |
| FY22 | 30.6% | −80.4% |
| FY21 | 90.8% | −71.9% |
| FY20 | 48.2% | −62.2% |
| FY19 | −36.9% | −46.3% |
| FY18 | −52.9% | −49.6% |
| FY17 | 19.9% | −45.9% |
| FY16 | −70.2% | −36% |
| FY15 | −23.9% | −38.4% |
| FY14 | −90.8% | −35.5% |
| FY13 | −152.3% | −37.1% |
| FY12 | −126.5% | −29.1% |
| FY11 | −35.2% | −27.9% |